PubMed · 14596254
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
2003. Emtriva gets approval.. https://pubmed.ncbi.nlm.nih.gov/14596254/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A new antiretroviral was approved July 2--the 19th now approved in the U.S. It is chemically related to 3TC.
A novel synthesis of 2'-deoxypseudoisocytidine as well as of its phosphoramidite building block for oligonucleotide synthesis is presented. The synthesis is based on Heck-coupling between N-protected pseudoisocytosine and a silyl protected furanoid glycal. With this procedure the corresponding phosphoramidite building block is obtained in 5 steps and an overall yield of 28%.
The FDA approved FTC (emtricitabine, Emtriva) in July 2003 for use by adults in combination with other anti-HIV drugs. FTC is a nucleoside analog reverse transcriptase inhibitor (NRTI). Other drugs in this class include 3TC, abacavir, AZT, Combivir, d4T, d4T XR, ddC, ddI, ddI EC and Trizivir.